Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation Therapy Oncology Group trial 90-03

Journal of Clinical Oncology

Volumn 27, Issue 26, 2009, Pages 4281-4286

  Le, Quynh Thu ^a   Harris, Jonathan ^a   Magliocco, Anthony M ^a   Kong, Christina S ^a   Diaz, Roman ^a   Shin, Brian ^a   Cao, Hongbin ^a   Trotti, Andy ^a   Erler, Janine T ^a   Chung, Christine H ^a   Dicker, Adam ^a   Pajak, Thomas F ^a   Giaccia, Amato J ^a   Ang, K Kian ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN LYSINE 6 OXIDASE; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; DEATH; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RADIATION DOSE FRACTIONATION; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; VALIDATION PROCESS; CAUSE OF DEATH; DISEASE COURSE; ENZYMOLOGY; HEAD AND NECK TUMOR; METABOLISM; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STAINING; STATISTICS; SURVIVAL; SURVIVAL RATE; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CAUSE OF DEATH; DISEASE PROGRESSION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN-LYSINE 6-OXIDASE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STAINING AND LABELING; SURVIVAL ANALYSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 70349307281     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.6003     Document Type: Article

References (41)

1. Forastiere A, Koch W, Trotti A, et al: Head and neck cancer. N Engl J Med 345:1890-1900, 2001
2. Argiris A, Haraf DJ, Kies MS, et al: Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: Reversing a pattern of failure. Oncologist 8:350-360, 2003
3. Brown JM, Giaccia AJ: The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Res 58:1408-1416, 1998
4. Le QT, Denko NC, Giaccia AJ: Hypoxic gene expression and metastasis. Cancer Metastasis Rev 23:293-310, 2004
5. Graeber TG, Osmanian C, Jacks T, et al: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379:88-91, 1996
6. Denko NC, Fontana LA, Hudson KM, et al: Investigating hypoxic tumor physiology through gene expression patterns. Oncogene 22:5907-5914, 2003
7. Erler JT, Bennewith KL, Nicolau M, et al: Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440:1222-1226, 2006
8. Camp RL, Dolled-Filhart M, King BL, et al: Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. Cancer Res 63:1445-1448, 2003
9. Psyrri A, Yu Z, Weinberger PM, et al: Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res 11: 5856-5862, 2005
10. Fu KK, Pajak TF, Trotti A, et al: A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. Int J Radiat Oncol Biol Phys 48:7-16, 2000
11. Le QT, Kong C, Lavori PW, et al: Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 69:167-175, 2007
12. Trotti A, Fu KK, Pajak TF, et al: A comparison of hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinoma. Proc Am Soc Thera Rad Onc (ASTRO), Denver, CO. Int J Radiat Oncol Biol Phys 63:S70-S71, 2005 (suppl 1; abstr 116)
13. Reference deleted
14. Cox DR: Regression models and life tables. J Royal Stat Soc 34:187-229, 1972
15. Lunt SJ, Chaudary N, Hill RP: The tumor microenvironment and metastatic disease. Clin Exp Metastasis 26:19-34, 2009
16. Cairns RA, Khokha R, Hill RP: Molecular mechanisms of tumor invasion and metastasis: An integrated view. Curr Mol Med 3:659-671, 2003
17. Rofstad EK, Rasmussen H, Galappathi K, et al: Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinasetype plasminogen activator receptor. Cancer Res 62: 1847-1853, 2002
18. Rofstad EK, Mathiesen B, Henriksen K, et al: The tumor bed effect: Increased metastatic dissemination from hypoxia-induced up-regulation of metastasispromoting gene products. Cancer Res 65:2387-2396, 2005
19. Rofstad EK, Mathiesen B, Galappathi K: Increased metastatic dissemination in human melanoma xenografts after subcurative radiation treatment: Radiation-induced increase in fraction of hypoxic cells and hypoxia-induced up-regulation of urokinase-type plasminogen activator receptor. Cancer Res 64:13-18, 2004
20. Cairns RA, Hill RP: Acute hypoxia enhances spontaneous lymph node metastasis in an orthotopic murine model of human cervical carcinoma. Cancer Res 64:2054-2061, 2004
21. Rofstad EK, Galappathi K, Mathiesen B, et al: Fluctuating and diffusion-limited hypoxia in hypoxiainduced metastasis. Clin Cancer Res 13:1971-1978, 2007
22. Lim YC, Koo BS, Choi EC: Bilateral neck node metastasis: A predictor of isolated distant metastasis in patients with oral and oropharyngeal squamous cell carcinoma after primary curative surgery. Laryngoscope 117:1576-1580, 2007
23. Al-Othman MO, Morris CG, Hinerman RW, et al: Distant metastases after definitive radiotherapy for squamous cell carcinoma of the head and neck. Head Neck 25:629-633, 2003
24. Brizel DM, Schroeder T, Scher RL, et al: Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int J Radiat Oncol Biol Phys 51:349-353, 2001
25. Fakhry C, Westra WH, Li S, et al: Improved survival of patients with human papillomaviruspositive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100: 261-269, 2008
26. Licitra L, Perrone F, Bossi P, et al: High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 24:5630-5636, 2006
27. Weinberger PM, Yu Z, Haffty BG, et al: Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 24:736-747, 2006
28. Chaturvedi AK, Engels EA, Anderson WF, et al: Incidence trends for human papillomavirusrelated and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 26:612-619, 2008
29. Li W, Nellaiappan K, Strassmaier T, et al: Localization and activity of lysyl oxidase within nuclei of fibrogenic cells. Proc Natl Acad Sci U S A 94:12817-12822, 1997
30. Giampuzzi M, Botti G, Di Duca M, et al: Lysyl oxidase activates the transcription activity of human collagene III promoter: Possible involvement of Ku antigen. J Biol Chem 275:36341-36349, 2000
31. Nellaiappan K, Risitano A, Liu G, et al: Fully processed lysyl oxidase catalyst translocates from the extracellular space into nuclei of aortic smoothmuscle cells. J Cell Biochem 79:576-582, 2000
32. Kagan HM, Williams MA, Calaman SD, et al: Histone H1 is a substrate for lysyl oxidase and contains endogenous sodium borotritide-reducible residues. Biochem Biophys Res Commun 115:186-192, 1983
33. Mello ML, Contente S, Vidal BC, et al: Modulation of ras transformation affecting chromatin supraorganization as assessed by image analysis. Exp Cell Res 220:374-382, 1995
34. Jeay S, Pianetti S, Kagan HM, et al: Lysyl oxidase inhibits ras-mediated transformation by preventing activation of NF-kappa B. Mol Cell Biol 23:2251-2263, 2003
35. Giampuzzi M, Oleggini R, Albanese C, et al: Beta-catenin signaling and regulation of cyclin D1 promoter in NRK-49F cells transformed by downregulation of the tumor suppressor lysyl oxidase. Biochim Biochim Biophys Acta 1745:370-381, 2005
36. Payne SL, Hendrix MJ, Kirschmann DA: Paradoxical roles for lysyl oxidases in cancer-a prospect. J Cell Biochem 101:1338-1354, 2007
37. Palamakumbura AH, Jeay S, Guo Y, et al: The propeptide domain of lysyl oxidase induces phenotypic reversion of ras-transformed cells. J Biol Chem 279:40593-40600, 2004
38. Lazarus HM, Cruikshank WW, Narasimhan N, et al: Induction of human monocyte motility by lysyl oxidase. Matrix Biol 14:727-731, 1995
39. Nelson JM, Diegelmann RF, Cohen IK: Effect of beta-aminopropionitrile and ascorbate on fibroblast migration. Proc Soc Exp Biol Med 188:346-352, 1988
40. Li W, Liu G, Chou IN, et al: Hydrogen peroxide-mediated, lysyl oxidase-dependent chemotaxis of vascular smooth muscle cells. J Cell Biochem 78:550-557, 2000
41. Erler JT, Bennewith KL, Cox TR, et al: Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 15:35-44, 2009